Patterns of HER2 testing in the management of primary breast cancer

Cancer Epidemiology

Volumn 33, Issue 2, 2009, Pages 113-117

  Pensa, Mellisa ^a   Swede, Helen ^a   Brockmeyer, Jessica A ^a   Gregorio, David I ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Breast carcinoma; Cancer; Race

Indexed keywords

ESTROGEN RECEPTOR; GAMMA UROGASTRONE; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER PATIENT; CANCER REGISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EUROPEAN AMERICAN; FEMALE; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; LYMPH NODE; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; POPULATION; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RACE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SOCIAL STATUS; SOCIOECONOMICS; TUMOR VOLUME; UNITED STATES;

AFRICAN AMERICANS; AGE FACTORS; BREAST NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PHYSICIAN'S PRACTICE PATTERNS; PROGNOSIS; RECEPTOR, ERBB-2; SOCIAL CLASS; TUMOR MARKERS, BIOLOGICAL;

EID: 68149154788     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2009.06.010     Document Type: Article

References (40)

1. Tetu B., and Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 73 (1994) 2359-2365
2. Emi Y., Kitamura K., Shikada Y., Kakeji Y., Takahashi I., and Tsutsui S. Metastatic breast cancer with HER2/neu-positive cells tends to have a morbid prognosis. Surgery 131 (2002) S217-S221
3. Heintz N.H., Leslie K.O., Rogers L.A., and Howard P.L. Positivity of the c-erb B-2 oncogene and prognosis of breast adenocarcinoma. Arch Pathol Lab Med 114 (1990) 160-163
4. Querzoli P., Ferretti S., Albonico G., Magri E., Scapoli D., Indelli M., et al. Application of quantitative analysis to biologic profile evaluation in breast cancer. Cancer 76 (1995) 2510-2517
5. Slamon D.J., Clark G.M., and Wong S.G. Human breast cancer: correlation of relapse and survival with positivity of the HER-2/neu oncogene. Science 235 (1987) 177-182
6. Shou J., Massarweh S., Osborne C.K., Wakeling A.E., Ali S., Weiss H., et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96 (2004) 926-935
7. Kurokawa H., Lenferink A.E., Simpson J.F., Piscane P.I., Sliwkowski M.X., Forbes J.T., et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60 (2000) 5887-5894
8. Benz C.C., Scott G.K., Sarup J.C., Johnson R.M., Tripathy D., Coronado E., et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24 (1992) 85-95
9. Pietras R.J., Arboleda J., Reese D.M., Wongvipat N., Pegram M.D., Ramos L., et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10 (1995) 2435-2446
10. Simon R., Nocito A., Hubscher T., Bucher C., Torhorst J., Schraml P., et al. Patterns of HER-2/neu positivity and over-expression in primary and metastatic breast cancer. J Natl Cancer Inst 93 (2001) 1141-1146
11. Robert N.J., and Favret A.M. HER2-positive advanced breast cancer. Hematol Oncol Clin North Am 21 (2007) 293-302
12. Engel R.H., and Kaklamani V.G. HER2-positive breast cancer: current and future treatment strategies. Drugs 67 (2007) 1329-1341
13. Carlson R.W., Moench S.J., Hammond M.E., Perez E.A., Burstein H.J., Allred D.C., et al. HER2 testing in breast cancer: NCCN task force report and recommendations. J Natl Compr Canc Netw 4 Suppl. 3 (2006) S1-S22 [quiz S23-S24]
14. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., et al. American society of clinical oncology/College of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25 (2007) 118-145
15. Allred D.C., Clark G.M., Molina R., Tandon A.K., Schnitt S.J., Gilchrist K.W., et al. Over-expression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23 (1992) 974-979
16. Ellis I.O., Bartlett J., Dowsett M., Humphreys S., Jasani B., Miller K., et al. Best practice no 176: updated recommendations for HER2 testing in the UK. J Clin Pathol 57 (2004) 233-237
17. National Cancer Institute (NCI). SEER Data, 1973-2005. Available at: http://seer.cancer.gov/publicdata (accessed 11 November 2008).
18. SPSS for Windows, Release 15 (2007), SPSS Inc., Chicago
19. Genentech, Inc. Your guide to the breast cancer pathology report. 2006. Available at: http://www.herceptin.com/pdf/pathology_report.pdf (accessed 9 June 2009).
20. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 (1999) 2639-2648
21. Bast Jr. R.C., Ravdin P., Hayes D.F., Bates S., Fritsche Jr. H., Jessup J.M., et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19 (2001) 1865-1878
22. Di Leo A., Dowsett M., Horten B., and Penault-Llorca F. Current status of HER2 testing. Oncology 63 Suppl. 1 (2002) 25-32
23. Taucher S., Rudas M., Mader R.M., Gnant M., Dubsky P., Bachleitner T., et al. Do we need HER-2/neu testing for all patients with primary breast carcinoma?. Cancer 98 (2003) 2547-2553
24. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.L., Harris L.N., Fehrenbacher L., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 719-726
25. Lewis R., Bagnall A.M., Forbes C., Shirran E., Duffy S., Kleijnen J., et al. The clinical effectiveness of trastuzumab for breast cancer: a systematic review. Health Technol Assess 6 (2002) 1-71
26. Gorin S.S., Heck J.E., Cheng B., and Smith S.J. Delays in breast cancer diagnosis and treatment by racial/ethnic group. Arch Intern Med 166 (2006) 2244-2252
27. Jacobellis J., and Cutter G. Mammography screening and differences in stage of disease by race/ethnicity. Am J Public Health 92 (2002) 1144-1150
28. Joslyn S.A. Racial differences in treatment and survival from early-stage breast carcinoma. Cancer 95 (2002) 1759-1766
29. Lannin D.R., Mathews H.F., Mitchell J., Swanson M.S., Swanson F.H., and Edwards M.S. Influence of socioeconomic and cultural factors on racial differences in late-stage presentation of breast cancer. JAMA 279 (1998) 1801-1807
30. Lukwago S.N., Kreuter M.W., Holt C.L., Steger-May K., Bucholtz D.C., and Skinner C.S. Sociocultural correlates of breast cancer knowledge and screening in urban African American women. Am J Public Health 93 (2003) 1271-1274
31. Smith-Bindman R., Miglioretti D.L., Lurie N., Abraham L., Barbash R.B., Strzelczyk J., et al. Does utilization of screening mammography explain racial and ethnic differences in breast cancer?. Ann Intern Med 144 (2006) 541-553
32. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Conwan D., Conway K., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295 (2006) 2492-2502
33. Smigal C., Jemal A., Ward E., Cokkinides V., Smith R., Howe H.L., et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 56 (2006) 168-183
34. Chlebowski R.T., Chen Z., Anderson G.L., Rohan T., Aragaki A., Lane D., et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 97 (2005) 439-448
35. Dignam J.J. Efficacy of systemic adjuvant therapy for breast cancer in African-American and Caucasian women. J Natl Cancer Inst Monogr 30 (2001) 36-43
36. Li C.I., Malone K.E., and Daling J.R. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev 11 (2002) 601-607
37. Shavers V.L., Harlan L.C., and Stevens J.L. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer 97 (2003) 134-147
38. Perez E.A. Cardiac toxicity of erbB2 targeted therapies: what do we know?. Clin Breast Cancer Suppl. 8 (2008) S114-S120
39. Dowsett M., Hanby A.M., Laing R., and Walker R. HER2 testing in the UK: consensus from a national consultation. J Clin Pathol 60 (2007) 685-689
40. Leong T.Y., and Leong A.S. Controversies in the assessment of HER-2: more questions than answers. Adv Anat Pathol 13 (2006) 263